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ROLE OF LYMPHOCYTE RECOVERY AFTER ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION IN PREDICTING RELAPSE IN
PEDIATRIC ACUTE LEUKIMIAS
Afzal, S.1, Ishaqi, M.K.1, Dupius, A.2, Doyle, J.1, Gassas, A.1 1Division
of Heamatology and Oncology/BMT, Hospital for Sick Children, To-
ronto, ON, Canada; 2Division of Clinical Research Support Unit, To-
ronto, ON, Canada.
Allogeneic hematopoietic stem cell transplantation (HSCT) is a
curative treatment for many children with relapsed or high risk
acute leukemias both myelogenous (AML) and lymphoblastic
(ALL). There are no reliable markers to predict relapse which
remain main cause of treatment failure post transplantation with
very poor outcome. We hypothesize that early lymphocyte recov-
ery measured by the absolute lymphocyte count (ALC) after
HSCT correlate with relapse and survival. Therefore, we evaluated
the effect of ALC and risk of relapse by studying ALC on day
21(ALC-21) and day 30(ALC-30) post HSCT in both ALL and
AML children. We reviewed 207 consecutive patients with acute
leukemias who received allogeneic HSCT between 1994 and 2005
in the Hospital for Sick Children, Toronto, Canada. One-thirty-
six transplantations were performed for ALL and 75 transplanta-
tions were performed for 71 children with AML. All patients at
time of HSCT were in complete morphological remission (CR)
except for one AML patient. Remission status were as follows;
CR1, n84; CR2, n103; CR3, n23 and one patient with AML
had 10% blast just prior to HSCT. Conditioning regimens in-
cluded; cylcophosphamide/TBI in 110 patients, VP16 and TBI in
59 patients, busulphan and cyclophosphamide in 28 patients and 14
children received other conditioning regimens. Donor stem cells
source were; matched sibling donor (MSD) in 98 patients, a mis-
matched related donor (MMRD) in 21 patients, and 88 children
received matched unrelated donor (MUD) and 4 children received
cord progenitor stem cells. For ALL, patients with ALC
0.3109/L at day 21 (n104) had more than 5 times risk of
relapse compared to those with ALC count 0.3  109/L (n32)
(Hazard ratio 1/0.19; P0.0004). Patients with ALC 0.310/L
(n48) at day 30 were more than twice likely to relapse compared
to those with ALC 0.3109/L (n88) (Hazard ratio 1/0.46;
P0.01). Whereas in AML; ALC 0.3109/L or 0.3109/L on
day 21 and 30 were not predictive of relapse with a Hazard ratio at
day 21; 0.88; P 0.8), Hazard ratio at day 30; 0.5; P 0.2. Con-
clusion: Slow lymphocyte recovery after HSCT appears to be
associated with a signiﬁcantly high risk of relapse in ALL but not
in AML as analyzed on day 21 and day 30 post HSCT. This group
of patients in ALL may beneﬁt from post transplant immune
manipulation to prevent relapse. However, in AML early lympho-
cyte recovery is not predictive of relapse.
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A SUBMYELOABLATIVE REGIMEN OF CAMPATH-1H AND FLUDARABINE
FOR PATIENTS WITH GRAFT FAILURE FOLLOWING ALLOGENEIC
TRANSPLANTATION FROM MHC IDENTICAL OR NEAR IDENTICAL DO-
NORS
Ahmed, N.1, Leung, K.S.1, Bollard, C.M.1, Gottschalk, S.1,
Myers, G.D.1, Carrum, G.2, Heslop, H.E.1, Brenner, M.K.1,
Krance, R.A.1 1Center for Cell and Gene Therapy, Baylor College of
Medicine, Houston, TX.
Primary or secondary graft failure or the persistence or reappear-
ance of mixed chimerism (MC) are potentially serious causes of
morbidity and mortality following hematopoietic stem cell trans-
plantation (HSCT). In a phase I/II pilot study we combined Flu-
darabine with the lympho-depleting humanized anti-CD52 anti-
body Campath-1H as a non-myeloablative therapy designed to
overcome donor-anti-recipient T cell responses and to permit
complete and successful donor engraftment following re-infusion
of donor stem cells. This study evaluated the safety, feasibility, and
rate of donor engraftment for twenty-two patients at our institution
from September 2000 to June 2006 (median age 3.5 years; range 7
months to 69 years; 14 males) with engraftment failure or mixed
chimerism (range 8-61% donor cell chimerism). All patients had
previously received one or more transplants for lympho-hemato-
logic malignancies (n14), immunodeﬁciency syndromes (n5) or
metabolic diseases (n3). Twelve patients were enrolled for graft
failure (55%) and ten for mixed chimerism (45%). Seven patients
were transplanted in relapse (3 with graft failure and 4 with mixed
chimerism). The conditioning regimen consisted of Fludarabine
and Campath-1H (30mg/m2/day and 10mg/day, respectively)
given on days –5 to –3. Twelve patients received transplants from
a single antigen mismatched family donor (55%), nine from a
matched unrelated (41%) and one from an HLA-identical sibling.
Donors were the same used for the primary transplant. Twenty-one
evaluable patients (95%) achieved sustained neutrophil engraft-
ment, and complete donor chimerism by day 28. Regimen-related
toxicities were tolerable. Nine patients (41%) never experienced
neutropenia. The median time to neutrophil engraftment for those
who experienced neutropenia was 10 days (range 2 to 20). The
overall survival for non-malignant transplant recipients was 100 %
and 43 % for patients with malignant disease, at a median fol-
low-up of 32 months (range, 4 to 73 months). Of the 8 patients
who died, 5 succumbed to relapse, while 1 died from infection, 1
from pulmonary and 1 from cardiac toxicity. Only one patient had
mild (grade I) acute graft-versus-host disease (aGVHD). We con-
clude that this reduced-intensity regimen enabled satisfactory en-
graftment and achievement of rapid complete donor chimerism
with minimal toxicities. It was associated with a low incidence of
aGHVD. The disease status was the main determinant of treat-
ment failure in this study.
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THE CONDITIONING REGIMEN INTENSITY OF ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION (ALLO-HCT) IN CHRONIC MYELOID
LEUKEMIA (CML): THE HISTORICAL CASE MATCHED COMPARISON OF
ABLATIVE VERSUS REDUCED INTENSITY REGIMEN
Gurman, G.1, Arat, M.1, Topcuoglu, P.1, Caglayan, E.A.1, Arslan, O.1,
Ozcan, M.1, Akan, H.1, Beksac, M.1, Konuk, N.1, Uysal, A.1, Koc, H.1,
Ilhan, O.1 1Ankara University, School of Medicine, Department of
Hematology, Stem Cell Transplantation Unit, Ankara, Turkey.
Allo-HCT is the only curative treatment approach yet. The use
of reduced intensive conditioning (RIC) regimen, which has the
main advantage of decrease in regimen related toxicity in compar-
ison with myeloablative (MA) regimens, is rising both in our
country and throughout the world. In this study we aimed to
retrospectively investigate the efﬁcacy of RIC on early and late
allogeneic transplant outcome in CML patients.Twenty-ﬁve pa-
tients conditioned with RIC regimen were matched to 48 patients,
who received a myeloablative regimen. The main criteria for case
matching among our CML allo transplant cohort were the Grat-
wohl scoring system (Gratwohl A. Lancet. 1998 352(9134):1087-
92). The donors were HLA identical siblings and the graft sources
were peripheral hematopoietic cell (n67) or bone marrow (n6).
Pretransplantation disease status was CP1 (n17), CP2 (n2), and
advanced phase (AP; accelerated phase plus blastic crisis) (n6) in
RIC group, and CP1 (n37), CP2 (n2) and AP (n18) in MA
group. All but one patient in MA group received BU&CY, while
FLU-based regimes were used in RIC group. Median age was 39
years (range, 24-57) and M/F was 11/14 in the RIC group, and
median age was 38.5 years (19-53 ys) and M/F was 30/18 in MA
group. The transplant-related data are shown in Table. The fre-
quency grade and period of mucositis were lower in RIC. As
expected days on total parenteral nutrition and febrile neutopenia
episodes were seen infrequently in RIC compared to MA. How-
81
ever, early transplant-related mortality (TRM) was similar in both
groups. Besides both the frequency of acute and chronic GvHD
were not affected by the intensity of conditioning regimen. In
median 24.2 months (0.2-36 ms) of follow-up period, 3-year-
probability of DFS and OS in RIC compared to MA were 34.7 %
vs 46.9 % (log-analysis, p0.31) and 61.2 % vs 47.2 % (p0.37),
respectively. Conclusion: We observed less regimen related tox-
icity in RIC group as expected. Although the incidence of disease
relapse was more frequent in RIC group than MA group, both
DFS and OS were found in similar rates in both regimen. In CML
patients RIC regimen could be preferable instead of a MA regimen,
in high risk transplant candidates. We have still no evidence for
RIC about durable control of CML. After the completion of an
ongoing prospective and randomized phase III study in CML
comparing the RIC with MA in our center; we will extensively
evaluate the impact of RIC at allogeneic transplantation.
Transplantation data
Variables RIC group (n25) p MA group (n48)
Median CD34 (10e6/
BW kg) (range)
4.63 (2.49-13.16) 0.283 4.85 (0.36-18.90)
Median MNC (10e8/
BW kg) (range)
4.31 (0.98-19.15) 0.953 4.79 (0.55-19.15)
Median CD3 (10e8/
BW kg) (range)
21.70 (1.00-100.26) 0.071 25.10 (1.0-294.54)
Median Gratwohl
Score (range)
2 (1-4) 0.795 2 (1-4)
Engraftment
kinetics
Neutrophil>
0.5109/L,
median days
(range)
15 (0-20) 0.699 14 (10-32)
Platelet> 20109/L,
median days
(range)
10 (0-15) <0.0001* 13.5 (8-32)
Mucositis (Present/
Absent)
11/14 <0.0001* 45/3
Median grade of
mucositis (range)
0 (0-3) <0.0001 2 (0-4)
Median days of
mucositis (range)
0 (0-14) <0.0001* 7 (0-20)
Febrile episode
(Present/Absent)
11/14 <0.0001* 45/3
Median incidence of
febrile episode, n
0 (0-2) <0.0001* 1 (0-3)
Median days of
febrile episode
(range)
0 (0-8) 0.008* 2 (0-15)
TPN use 22% <0.0001* 77%
Acute GvHD 34.8% 0.785 29.8%
Chronic GvHD 76.2% 0.504 72.5%
Early transplant-
related mortality
12.0% 0.522 20.8%
Relapse 52% 0.001* 26%
3-year- probability
of DFS
34.67%  10.62% 0.314 46.85%  7.89%
3-year- probability
of OS
61.24%  10.24% 0.367 47,19%  7.85%
*p0.05
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C-REACTIVE PROTEIN (CRP) MAY PREDICT TRANSPLANT-RELATED
MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
(HCT)
Artz, A.S.1, Wickrema, A.1, Stock, W.1, Daugherty, C.1, Godley, L.1,
Kocherginsky, M.1, Odenike, O.1, Pollyea, D.1, Rich, E.1, Ulsazek, J.1,
Larson, R.1, van Besien, K.1 1University of Chicago Pritzerk School of
Medicine, Chicago, IL.
Current prognostic factors for transplant related mortality
(TRM) are disease status, the presence of comorbid conditions, and
performance status. Each of these measures has problems of sen-
sitivity and discriminative capacity. CRP, a marker of systemic
inﬂammation, has shown considerable value in non-HCT setting
to predict vascular events and overall survival(OS). We hypothe-
sized that elevated CRP would predict for worse HCT outcome.
Using a highly sensitive CRP assay, pre-HCT CRP levels were
analyzed in 41 consecutive patients with MDS or AML who un-
derwent HCT after a preparative regimen of ﬂudarabine (125
mg/m2 IV total), melphalan (140 mg/m2 IV total) and alemtu-
zumab (100 mg IV total). The median age was 52 years and 11/41
had active had active disease at HCT. The median CRP level was
20.6 mg/L and the mean was 38.5 mg/L (range 0.3 to 180). Six
month TRM was 23% with a median follow-up for survivors of 15
months. There was a signiﬁcant association between higher pre-
HCT CRP levels and TRM (P 0.03). CRP levels above the
median had a hazard ratio of 3.2 (P  0.07). CRP also showed an
association with overall survival (OS) (P 0.07) of borderline
statistical signiﬁcance. CRP remained predictive of TRM after
adjusting for disease status (P  0.06), charlson comorbidity index
(P  0.03), kaplan-feinstein comorbidity index (P  0.01), ECOG
performance status (P0.07) and age over 50 (P0.04). We con-
clude that in HCT recipients, the independent prognostic value of
CRP for TRM suggests the potential to enhance estimates of HCT
outcome in addition to standard prognostic factors. Prospective
studies in larger patient cohorts should be pursued to conﬁrm the
independent value of CRP and other pro-inﬂammatory cytokines
on HCT outcome.
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THIOTEPA BASED CONDITIONING REGIMEN IN 374 PATIENTS UNDER-
GOING ALLOGENEIC STEM CELL TRANSPLANTS FROM RELATED OR
UNRELATED DONORS
Bacigalupo, A.1, Gualandi, F.1, Occhini, D.1, Bregante, S.1,
Lamparelli, T.1, Raiola, A.M.1, Ibatici, A.1, Di Grazia, C.1,
Dominietto, A.1, Bruno, B.1, van Lint, M.T.1, Frassoni, F.1 1Hematol-
ogy Division, S.Martino’s Hospital, Genova, Italy.
Background:The Perugia group introduced thiotepa (THIO) in
allogeneic stem cell transplants (HSCT): we have developed
THIO based conditioning regimens in combination with cyclo-
phopshamide (CY), Fludarabine (FLU), melphalan (MEL) or TBI
200 mainly for patients above the age 45.
Aim of the study: assess the outcome of patients undergoing an
allogeneic HSCT with a THIO based conditioning regimen.
Patients. 374 patients were allografted with a THIO based
regimen, between 1994 and 2005, from HLA identical siblings
(SIB) (n221) or family partially mismatched (n67) or unrelated
(n86) donors. Median patient age was 48 years (range16-.67).
The stem cell source was unmanipulated in all cases , either bone
marrow (n276) or peripheral blood (n98). The conditioniong
regimens were classiﬁed as reduced intensity (n177) (THIO-CY
or THIO-FLU) or intensiﬁed (n197) (THIOCY supple-
mented with MEL or TBI). The disease was in 1stCR (n221) or
more advanced phase (n153). Patients had chronic myeloprolif-
erative disorders (n123), acute leukemia (n120), myelodisplasia
(n46), other (n85, including lymphoma and myeloma). All,
patients received cyclosporin methotrexate GvHD prophylaxis;
anti-thymocyte globulin was added for alternative donor trans-
plants. The median follow up for surviving patients is 5 years
(range 1-12 years)
Results: The overall actuarial 10 year survival is 40%, (60% vs
30% in CR1 or CR1 disease). The cumulative incidence (CI) of
transplant related mortality (TRM) at 10 years is 29% (18% vs 36%
for CR1 or CR1 disease); TRM for CR1 patients grafted from
identical siblings (n94) is 12%. Acute GvHD grade III-IV was
seen in 6% of sibling HSCT and 12% of alternative donor grafts.
The CI of relapse related death (RRD) at 10 years was 27% (18% vs
32% in CR1 or CR1). There was no effect of patient age, nor of
stem cell source on survival. In multivariate analysis on survival,
signiﬁcant predictors were disease phase (RR 2.4 of death for
patients beyond CR1) and intensity of the conditioning (RR 1.66
for intensiﬁed regimens); these two variables also predicted TRM;
disease phase predicted RRD.
Conclusions: This study shows that THIO based conditioning
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